Fjarde AP Fonden Fourth Swedish National Pension Fund Purchases around 9,808 Shares of the BioMarin Pharmaceutical Incorporation

Fjarde AP Fonden Fourth Swedish National Pension Fund raised its holdings in BioMarin Pharmaceutical Inc. by 21.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 55,869 shares of the biotechnology company’s stock after purchasing an additional 9,808 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in BioMarin Pharmaceutical were worth $4,963,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Commonwealth Bank of Australia increased its stake in shares of BioMarin Pharmaceutical by 49.6% during the fourth quarter. Commonwealth Bank of Australia now owns 350 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 116 shares during the period.

Tokio Marine Asset Management Co. Ltd. increased its stake in shares of BioMarin Pharmaceutical by 0.5% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 27,142 shares of the biotechnology company’s stock worth $2,411,000 after acquiring an additional 144 shares during the period. Nordea Investment Management AB increased its stake in shares of BioMarin Pharmaceutical by 2.1% during the third quarter.

Nordea Investment Management AB now owns 7,206 shares of the biotechnology company’s stock worth $699,000 after acquiring an additional 147 shares during the period. State of Alaska Department of Revenue increased its stake in shares of BioMarin Pharmaceutical by 0.8% during the fourth quarter. State of Alaska Department of Revenue now owns 21,807 shares of the biotechnology company’s stock worth $1,856,000 after acquiring an additional 175 shares during the period. Finally, First Hawaiian Bank increased its stake in shares of BioMarin Pharmaceutical by 2.3% during the first quarter.

First Hawaiian Bank now owns 8,935 shares of the biotechnology company’s stock worth $794,000 after acquiring an additional 200 shares during the period.